Biotech Values

[DewDiligence]

Now the question is whether NVS/MNTA will sue Amphastar for patent infringement to try to block Amphastar from launching generic Lovenox. To my knowledge, Amphastar is not a defendant in NVS/MNTA’s suit against Teva.

p.s. The above assumes that Amphastar's approval is for a substitutable generic Lovenox. If the approved product is not substitutable for branded Lovenox, then there is no significant economic harm to NVS/MNTA.